孕早期血清可溶性内皮糖蛋白和可溶性fms样酪氨酸激酶-1水平作为晚发型子痫前期的孕早期标志物。
First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia.
作者信息
Baumann Marc U, Bersinger Nick A, Mohaupt Markus G, Raio Luigi, Gerber Susan, Surbek Daniel V
机构信息
Department of Obstetrics and Gynecology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.
出版信息
Am J Obstet Gynecol. 2008 Sep;199(3):266.e1-6. doi: 10.1016/j.ajog.2008.06.069.
OBJECTIVE
The aim of this investigation was to assess soluble endoglin (sEng) and soluble fms-like tyrosine kinase-1 (sFlt1) as first-trimester serum markers to predict preeclampsia.
STUDY DESIGN
First-trimester sera were obtained from 46 women with subsequent late-onset preeclampsia and from 92 controls. sEng and sFlt1 concentrations were determined immunoanalytically. Correlation analysis with inhibin A and placental growth factor levels was performed.
RESULTS
sEng and sFlt1 serum concentrations were higher in women with subsequent preeclampsia than in controls (mean +/- SD, sEng: 5.57 +/- 1.18 ng/mL vs 5.02 +/- 1.01 ng/mL, P = .009; sFlt1: 1764 +/- 757 pg/mL vs 1537 +/- 812 pg/mL, P = .036). Sensitivities and specificities for predicting preeclampsia were 63% and 57% for sEng and 64% and 56% for sFlt1, respectively. When sEng and inhibin A were combined, the sensitivity increased to 68%, whereas the specificity was 61%.
CONCLUSION
sEng and sFlt1 are increased in the first trimester in women with subsequent late-onset preeclampsia and might therefore prove useful to predict preeclampsia.
目的
本研究旨在评估可溶性内皮糖蛋白（sEng）和可溶性fms样酪氨酸激酶-1（sFlt1）作为孕早期血清标志物预测子痫前期的价值。
研究设计
收集46例随后发生晚发型子痫前期的孕妇及92例对照孕妇的孕早期血清。采用免疫分析法测定sEng和sFlt1浓度。并与抑制素A和胎盘生长因子水平进行相关性分析。
结果
随后发生子痫前期的孕妇血清中sEng和sFlt1浓度高于对照组（均值±标准差，sEng：5.57±1.18 ng/mL对5.02±1.01 ng/mL，P = 0.009；sFlt1：1764±757 pg/mL对1537±812 pg/mL，P = 0.036）。sEng预测子痫前期的敏感性和特异性分别为63%和57%，sFlt1分别为64%和56%。当sEng与抑制素A联合检测时，敏感性提高到68%，而特异性为61%。
结论
随后发生晚发型子痫前期的孕妇在孕早期sEng和sFlt1水平升高，因此可能有助于预测子痫前期。
Zotero 插件